Test Directory

Test Code
1568
Test Name
Larsen Syndrome, Autosomal Recessive
CPT Codes
81479
Expected Turnaround Time
Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited.
Clinical Utility
Genetic analysis to provide a molecular diagnosis of this disorder. Recommended for individuals with a personal and/or family history of this disorder to ensure appropriate treatment and establish recurrence risk for family members.
Specimen and Container Info

Non-Prenatal Specimens

Preferred/Alternate

Specimen Type

Containers

Volume

Preferred Specimen Type

Whole Blood

Lavender Top (EDTA)

3 mL

Alternate Specimen Type

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

Alternate Specimen Type

Fibroblasts

T-25 Flasks

2 confluent T-25 flasks, filled to capacity

Alternate Specimen Type

Saliva (Whole blood is recommended for CNV)

DNA Self-Collection Kit or Oragene Saliva Collection Kit for Young Children

Follow kit instructions (www.dnagenotek.com)

Prenatal Specimens

Either specimen type below is acceptable.

Specimen Type

Containers

Volume

Cultured cells

T-25 Flasks

2 confluent T-25 flasks derived from amnio or CVS samples.

Genomic DNA

1.5 mL Tube

3 µg (at a concentration of at least 30 ng/µl), preferably in TE solution.

NOTE: For specimens from outside of North America, the preferred specimen type is Genomic DNA. HNL Genomics does not recommend shipping whole blood or cultured cells from any location other than the United States, Canada, or Mexico.

Transport Instructions
  • Transport at room temperature within 24 hours.
  • If the specimen cannot be transported to the lab within 24 hours, refrigerate for up to 72 hours.
  • Do not freeze or expose to extreme temperatures, refrigerate for up to 72 hours if cannot be transported to lab within 24 hours. 
Stability Requirements

Room Temperature

24 hours

Refrigerated

72 hours

Causes for Rejection
  • Improperly labeled specimen (minimum of two patient identifiers)
  • Inappropriate specimen type
  • Incomplete or incorrect test request form
  • Insufficient volume
  • Specimen has leaked in transit
  • Specimen without a test order
Methodology
Next Generation Sequencing and Copy Number Variation Analysis
Performing Location
Genomics - Snowdrift
Description

Larsen syndrome, autosomal recessive and spondyloepiphyseal dysplasia with congenital joint dislocations (includes humerospinal dysostosis, spondyloepiphyseal dysplasia, Omani type and chondrodysplasia with multiple dislocations). Larsen syndrome, autosomal recessive (MIM 245600) and spondyloepiphyseal dysplasia with congenital joint dislocations (MIM 143095) which includes humerospinal dysostosis (HSD), spondyloepiphyseal dysplasia, Omani type and chondrodysplasia with multiple joint dislocations are allelic disorders with similar clinical findings. All are caused by mutations in the carbohydrate sulfotransferase 3 gene (CHST3). It has been suggested that they may represent a single disorder with various age dependent manifestations. Alternatively, different loss of function mutations with various severities may cause a clinical spectrum. When patients are evaluated in the neonatal period or as young children, they are often diagnosed with Larsen syndrome, humerospinal dysostosis or chondrodysplasia with multiple dislocations. Patients with Larsen syndrome or humerospinal dysostosis typically have a birth length below the 3rd percentile. Growth often remains below the 3rd percentile throughout childhood and adults typically have short stature. The characteristic feature of patients with CHST3 mutations are congenital dislocations. Almost all patients have congenital knee dislocations and clubfoot. Dislocations or contractures of the elbows and hips are also common. Patients evaluated during childhood typically have features of spondyloepiphyseal dysplasia, Omani type. Older patients have severe degeneration of the intervertebral discs with thoracic kyphoscoliosis. Posterior and inferior scalloping or coronal clefting of lumbar vertebrae and widening of the interpedicular distance from T12 to L1 or L2 are evident on X-ray. Fusion of vertebral bodies eventually occurs. Several patients with CHST3 mutations have also been described with abnormalities of the heart valves. Older patients may present with dislocations that have improved either spontaneously or following surgical intervention. Arthritis of the hips and spine, intervertebral disc degeneration with trunk shortening and rigid kyphoscoliosis also dominates the clinical picture. Patients with CHST3 mutations must be differentiated from patients with classic autosomal dominant Larsen syndrome and Desbuquois dysplasia. Autosomal dominant Larsen syndrome is caused by mutations in the FLNB gene. Those with CHST3 mutations can be differentiated by the lack of facial flattening and the lack of advanced carpal age. In addition, patients with classic Larsen syndrome do not have the vertebral changes seen in patients with CHST3 mutations. Desbuquois dysplasia is an autosomal recessive chondrodysplasia caused by mutations in the CANT1 gene. Individuals with Desbuquois dysplasia have vertebral clefting, facial flattening and advanced carpal age which differentiates these patients from individuals with CHST3 mutations.

Testing Schedule
Monday-Friday
Genes
CHST3
MIM
245600
Disease Group
Skeletal Disorders